Details

Autor(en) / Beteiligte

• El Bairi, Khalid
• Najem, Salma
• Chowdhury, Arman Reza
• Omar, Abeid
• Abdihamid, Omar
• Teuwen, Laure-Anne
• Benhima, Nada
• Madariaga, Ainhoa
• Elkefi, Safa
• Diaz, Fernando Cristobal
• Hussain, Sadaqat
• Jenei, Kristina
• Hammad, Nazik
• Mutebi, Miriam
• Rubagumya, Fidel
• Trapani, Dario
• El Kadmiri, Nadia
• Laouali, Nasser
• Fourtassi, Maryam

Titel

Conflict of Interest Disclosure in Oncology: Preliminary Insights From the Global ONCOTRUST-1 Cross-Sectional Study

Ist Teil von

• JCO global oncology, 2024-07, Vol.10 (10), p.e2400167

Ort / Verlag

United States: American Society of Clinical Oncology

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Conflicts of interest (COIs) between oncologists and industry might considerably influence how the presentation of the research results is delivered, ultimately affecting clinical decisions and policy-making. Although there are many regulations on reporting COI in high-income countries (HICs), little is known about their reporting in low- and middle-income countries (LMICs). Oncology Transparency Under Scrutiny and Tracking (ONCOTRUST-1) is a pilot global survey to explore the knowledge and perceptions of oncologists regarding COI. We designed an online 27-question-based survey in the English language to explore the perceptions and knowledge of oncologists regarding COI, with an emphasis on LMICs. Descriptive statistics and the Consensus-Based Checklist for Reporting of Survey Studies guidelines were used to report the findings. ONCOTRUST-1 surveyed 200 oncologists, 70.9% of them practicing in LMICs. Median age of the respondents was 36 (range, 26-84) years; 47.5% of them were women. Of the respondents, 40.5% reported weekly visits by pharmaceutical representatives to their institutions. Regarding oncologists' perceptions of COI that require disclosure, direct financial benefits, such as honoraria, ranked highest (58.5%), followed by gifts from pharmaceutical representatives (50%) and travel grants for attending conferences (44.5%). By contrast, personal or institutional research funding, sample drugs, consulting or advisory board, expert testimony, and food and beverage funded by pharmaceutical industry were less frequently considered as COI. Moreover, only 24% of surveyed oncologists could correctly categorize all situations representing a COI. These findings underscore the importance of clear guidelines, education, and transparency in reporting COI in oncology. This hypothesis-generating pilot survey provided the rationale for ONCOTRUST-2 study, which will compare perceptions of COI among oncologists in LMICs and HICs.